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ABSTRACT
MDI 301 is a picolinic acid-substituted ester of 9-cis retinoic acid. It has been
shown in the past that MDI 301 increases epidermal thickness, decreases matrix
metalloproteinase (MMP) activity, and increases procollagen synthesis in organ-
cultured human skin. Unlike all-trans retinoic acid (RA), MDI 301 does not in-
duce expression of proinflammatory cytokines or induce expression of leukocyte
adhesion molecules in human skin. In the present study we examined topical
MDI 301 treatment for ability to improve the structure and function of skin in
three models of skin damage in rodents and for ability to improve abrasion
wound healing in these models. MDI 301 was applied daily to the skin of rats
treated with the potent corticosteroid, clobetasol propionate, to the skin of dia-
betic rats (8 weeks posttreatment with streptozotocin) and to the skin of aged
(14–16-month-old) rats. In all three models, subsequently induced abrasion
wounds healed more rapidly in the retinoid-treated animals than in vehicle-treat-
ed controls. Immediately after complete wound closure, tissue from the wound
site (as well as from a control site) was put into organ culture and maintained
for 3 days. At the end of the incubation period, culture fluids were assessed for
soluble type I collagen and for MMPs-2 and -9. In all three models, the level of
type I collagen was increased andMMP levels were decreased by MDI 301. In all
three models, skin irritation during the retinoid-treatment phase was virtually
nonexistent.
Minor abrasions that occur in healthy skin are expected to
heal without incident. Interventions are designed primarily
to prevent infection and to provide support for the body’s
own regenerative mechanisms. In contrast, wounds in
chronically damaged and atrophic skin often go on to
form nonhealing ulcers with devastating consequences.
Diabetes alone is a contributing factor in up to 70% of
the > 55,000 amputations that occur annually.1–4 Skin
that has become atrophic as a consequence of the aging
process also demonstrates impaired wound healing,5–7 as
does skin that has been damaged as a result of extended
corticosteroid use.8–10 The majority of wound-healing re-
search is directed toward understanding the patho-physi-
ology of impaired wound healing and identifying
interventions that can mitigate the critical patho-physio-
logical events.
Several past studies have demonstrated the efficacy of
all-trans retinoic acid (RA) and its parent compound all-
trans retinol (ROL, vitamin A) in wound healing. Al-
though most studies have focused on wounds in the
skin,11–17 retinoid efficacy has also been demonstrated in
healing of wounds in other tissues (bone, cornea, respira-
tory tract, upper digestive system, and gut).18–25 While re-
tinoids have the potential of improving skin structure and
function, a consequence of topical retinoid use is skin irri-
tation.26 Irritated skin is characterized by redness, dryness,
and flaking at the treated site. At the histological level, one
sees a perivascular accumulation of mononuclear cells,
with neutrophils and monocytes scattered throughout the
dermis and occasional micro-abscesses in the dermis or
epidermis. ROL tends to be less irritating than RA in most
cases, but even with this agent, significant irritation is ob-
served in many individuals.27 Likewise, skin irritation is
also a complication with synthetic retinoidal agents cur-
rently on the market.28 Irritation is a major cause of non-
compliance among retinoid users. In addition, excessive
irritation may counteract the beneficial effects of retinoid
use or actually predispose the tissue to abrasion wounding.
MDI 301 is a picolinic acid-substituted 9-cis retinoic
acid ester. In a recent study, this agent was shown to in-
crease epidermal proliferation, decrease matrix metal-
loproteinase (MMP) activity and increase procollagen
synthesis in organ-cultured human skin.29 Unlike RA,
MDI 301 did not induce expression of proinflammatory
cytokines or lead to up-regulation of leukocyte adhesion
molecules in the treated skin. When applied topically to
the skin of hairless mice, essentially no skin irritation was
observed.30 In the present study we examinedMDI 301 for
ability to improve healing of superficial abrasion wounds
in three models of delayed wound healing in rodents. MDI
301 was applied daily to the skin of rats treated with the
potent corticosteroid, clobetasol propionate (Temovate),
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to the skin of rats made diabetic by treatment with
streptozotocin (STZ) or to the skin of aged rats. In all
three models, subsequently induced abrasion wounds
healed more rapidly in the MDI 301-treated animals than
in vehicle-treated controls. In all three models, skin irrita-




MDI 301 is a 9-cis RA derivative in which the terminal
carboxylic acid group has been replaced by a picolinic es-
ter. MDI 301 was synthesized as described in the original
patent (US Patent 5,837,728; Molecular Design Interna-
tional, Memphis, TN) and our previous report.30 For
topical treatment, MDI 301 was dissolved in dimethyl
sulfoxide (DMSO) at a 1.0% concentration and frozen
at 80 1C protected from light. RA was purchased from
Sigma Chemical Company (St. Louis, MO) and handled
exactly as with MDI 301.
Hairless mice and hairless rats
Four- to 6-week-old male HRLS strain hairless mice were
obtained from Taconic Farms Inc., Hudson, NY. Male
CD hairless rats (250–300 g) were purchased from Charles
River Laboratories, Portage, MI. Mice and rats were
housed in temperature and light-controlled rooms and giv-
en water and feed ad libitum. All studies involving animals
were approved by the University Committee on Use and
Care of Animals.
Corticosteroid-induced skin damage
Temovate (0.05% solution of clobetasol propionate in
cream base) was obtained from Glaxo Smith Kline
(Philadelphia, PA). For 15 consecutive days, animals
were treated with approximately 0.1mL (mice) or 0.5mL
(rats) of Temovate cream, applied to the back and
flanks of the animals. At the end of the treatment
period, mice were sacrificed and skin from the animals
was used for histology or for organ culture as described
below. In experiments with rats, the animals were
subdivided into groups and used in wounding studies as
described below.
Streptozotocin (STZ)-induced diabetes
Rats were rendered diabetic by a single intraperitoneal in-
jection of STZ (70mg/kg of body weight). For study in-
clusion, diabetic rats had a nonfasting blood glucose
concentration of > 250mg/dL in tail vein blood (mea-
sured by Glucometer; LifeScan Inc., Milpitas, CA) at 72
hours after STZ injection. Animals were individually
housed with ad libitum access to water and suitable rat
chow for the next 8 weeks. Weight and capillary glucose
values were checked on a weekly basis until the end of the
8-week period. Diabetic rats were given small daily doses
(0.5–1.0U/day) of protamine zinc insulin (Aventis Phar-
maceuticals, Kansas City, MO) as necessary to maintain
blood glucose levels at approximately 300–350mg/dL. At
the end of the treatment period, animals were subdivided
into groups and used in wounding studies as described be-
low. Our previous studies have demonstrated that 8 weeks
is sufficient for deficits in the skin to develop in STZ-treat-
ed animals.17
Aged skin model
Aged rats were purchased from Charles River Laborato-
ries as retired breeders at 10–12 months of age and then
aged for an additional 4 months in housing at the Unit for
Laboratory animal Medicine (University of Michigan). At
that time, the animals had reached a weight of approxi-
mately 600 g. Animals were then randomly assigned to
groups and topically treated and used in abrasion wound
studies as described below. Young (4–6-week-old) animals
were used as controls. They were purchased immediately
before use.
Skin irritation and epidermal thickness in hairless mice
Dilutions of the 1.0% solution of MDI 301 were prepared
in DMSO. Once daily for 14 days, hairless mice were top-
ically treated over the back and flank with 100mL of the
retinoid solutions. Some mice were treated with a 100mL
of a 0.1% solution of RA and others received 100mL of
DMSO alone. Each day during the retinoid-treatment
phase, the animals were examined for signs of skin irrita-
tion. Irritation was characterized by redness, dryness (with
small cracks developing in the skin), and epidermal flak-
ing. On day 15, the animals were carefully evaluated for
these features and given an overall ‘‘irritation score’’ of 11
to 41. A 11 score indicated no difference between the ret-
inoid-treated animals and the vehicle-treated controls; a
score of 41 indicated maximal irritation.
One day after the last treatment (i.e., on day 15), ani-
mals were sacrificed and skin samples from the treated site
removed. One piece of skin from each animal was imme-
diately fixed in 10% buffered formalin and used for histo-
logical evaluation. Epidermal thickness was assessed
quantitatively in the skin samples following sectioning
and staining with hematoxylin and eosin. A second piece
of skin from each animal was cut into pieces approximate-
ly 2mm on a side. Four–five such tissue pieces were incu-
bated for 3 days in 0.5mL of a culture medium consisting
of growth factor-free, serum-free keratinocyte basal medi-
um (Cambrex Inc., East Rutherford, NJ). Before use, the
culture medium was supplemented with Ca21 to a final
concentration of 1.4mM. At the end of the 3-day incuba-
tion period, the organ culture fluid was collected and as-
sayed for soluble type I collagen, MMPs-2 and -9 as
described below.
Abrasion wound model
Abrasion wounding was performed in hairless rats as de-
scribed previously.17 Briefly, under general anesthesia
(ketamine/xylazine), paravertebral skin from the back
and flanks was cleaned with 70% ethanol. A premeasured
circular area, approximately 2 in. in diameter was
scrubbed with a stiff-nylon bristle brush lightly wetted
with acetone and concomitantly abraded with a piece of
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course sanding sponge. Abrasion was sufficient to remove
the thin epidermis, the basement membrane and the upper
most part of the subepithelial stroma. Oozing of fluid (with
a small amount of blood) into the abraded area indicated
that the appropriate degree of abrasion was achieved. The
degree of injury approximates that commonly occurring
after a minor scrape. Wounding was performed under
sterile conditions in a laminar flow hood. Wound size was
determined daily by measuring the X and Y-axis of the
scabbed wound with calipers and calculating the area of
the remaining scab. At the time of wound closure, animals
were sacrificed and skin samples were removed and pro-
cessed as described above for hairless mice. One piece of
tissue from each site was fixed in 10% buffered formalin
and used for histology. A second piece was incubated in
organ culture for 3 days. At the end of the incubation pe-
riod, the culture fluid was assayed for soluble type I colla-
gen and MMPs as indicated below.
Soluble type I collagen
Culture fluids were assayed for type I collagen by Western
blotting. Briefly, organ culture fluids representing equal
quantity of protein were resolved using 8% sodium do-
decyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) under nonreducing conditions and transferred to
nitrocellulose membranes. The membranes were blocked
with 5% nonfat milk solution in Tris-buffered saline with
0.1% Tween (TTBS) for 1 hour at room temperature. Fol-
lowing this, they were incubated overnight with a rabbit
antibody to rodent type I collagen (1 : 10,000 dilution)
(Abcam Inc., Cambridge, MA) in the same buffer at 4 1C.
The membranes were then washed with TTBS and bound
antibody was detected using the Phototope-HRP Western
detection kit (Cell Signaling Technologies Inc., Danvers,
MA). Images were scanned, digitized, and quantified using
NIH image analysis software.
MMP production
Substrate embedded enzymography (zymography) was
used to assess levels of latent and active MMPs-2 and -9
in organ culture fluids. As described previously,17 SDS-
PAGE gels were prepared with the incorporation of
gelatin (1mg/mL) at the time of casting. After electropho-
resis under nonreducing conditions to separate proteins
and overnight incubation to allow for substrate diges-
tion, zones of hydrolysis were identified as ‘‘holes’’ in
the stained gels and quantified. Values for latent and
active MMPs-2 and -9 bands were obtained following
digitization.
Statistical analysis
Data were analyzed using one-way analysis of variance
(ANOVA) followed by the Bonferroni posttest for selected
pairs (GraphPad Prism version 4.00 for Windows, Graph-
Pad Software, San Diego, CA). For experiments in which
there were only two groups, the Student t-test was used to
assess statistical significance of the differences. Data were
considered significant at p < 0.05.
RESULTS
Topical treatment with MDI 301 induces epidermal
hyperplasia but not irritation in hairless mice
In the first series of experiments, hairless mice were treated
topically with concentrations of MDI 301 ranging from
0.01 to 1.0%. Vehicle-treated mice and animals treated
with 0.1% RA served as controls. One day after the last
treatment (day 15), mice were evaluated grossly for signs
of irritation. As shown in Figure 1A, concentrations as
high as 0.3% MDI 301 produced no evidence of irritation
while RA was (as expected) irritating at 0.1%. Additional
mice were treated with MDI 301 at a concentration of
1.0%, and this concentration also induced minimal irrita-
tion (Figure 1A).
Mice were sacrificed after gross evaluation for irritation
and tissue from treated sites evaluated histologically for
epidermal hyperplasia (Figure 1B). Topical treatment of
hairless mice with either retinoid induced a robust hyper-
plasia. With MDI 301, increased epidermal thickening
could be seen at a concentration of 0.1% and was statisti-
cally significant at concentrations of 0.3% or higher. As
expected, RA induced epidermal hyperplasia at 0.1%.
Topical treatment with MDI 301 stimulates collagen
production in hairless mice
In the next experiments, hairless mice were treated daily
for 15 days with Temovate and during the last 12 days with
0.3 or 1.0% MDI 301. As expected, the combination of
Temovate and MDI 301 produced no evidence of skin ir-
ritation (not shown). At the end of the treatment period,
skin samples from the treated site were obtained for histo-
logical evaluation. Additional skin samples were incubat-
ed in organ culture for 3 days and then analyzed for
soluble type I collagen. As seen in Figure 2A, both con-
centrations of MDI 301 induced epidermal thickening in
the Temovate-treated skin. Both concentrations also stim-
ulated type I collagen production (Figure 2B). To establish
that the ability of MDI 301 to induce epidermal thickening
and collagen production (without irritation) was not
unique to mice, a small cohort of CD hairless rats (three
rats per group) were also treated with the combination of
Temovate (15 days) and MDI-301 (0.3%) during the final
12 days. Similar to what was observed in hairless mice,
epidermal thickening and collagen production were both
stimulated by MDI 301 in Temovate-treated rats (not
shown). Based on these consistent findings in control and
Temovate-treated hairless mice and rats, we undertook
subsequent wound healing experiments in hairless rats, us-
ing MDI 301 at a concentration of 0.3%.
Healing of superficial abrasion wounds in
corticosteroid-treated skin and in diabetic skin:
stimulation of wound healing by MDI 301
Skin atrophy was induced in hairless rats by treatment for
15 days with Temovate exactly as described above. Some
of the animals were also treated with 0.3% MDI 301 once
daily during the final 12 days. Others were treated with ve-
hicle (DMSO) alone. At the end of the treatment phase,
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abrasion wounds were induced in the vehicle-treated and
MDI 301-treated animals (as well as in hairless rats that
had not been exposed to the steroid) and healing times as-
sessed. The data from these studies are presented in Figure
3A. Wound closure was slower in the steroid-treated ani-
mals than in non-steroid–treated controls. Wound closure
was significantly improved in those steroid-treated rats
that also received MDI 301 as compared with steroid-
treated rats that received vehicle alone (i.e., time to com-
plete closure was reduced in the retinoid-treated animals).
Differences could be seen by days 3 and 4, difference be-
tween vehicle-treated and MDI 301-treated animals was
statistically significant (Figure 3A).
Figure 3B summarizes findings from studies in which
superficial abrasion wounds were created in the skin of
nondiabetic and STZ-diabetic hairless rats. For this study,
rats were made diabetic with a single does of STZ. Begin-
ning 8 weeks after STZ injection, the animals were treated
for 14 days with vehicle alone or with MDI-301. Abrasion
Figure 1. Skin irritation and epidermal thickness in hairless
mice treated with MDI 301. (A) Skin irritation. Values are means
and standard deviations based on visual observations of three
mice per treatment group (scored on a 11 to 41 scale). (Inset)
Skin of mice treated for 7 days with vehicle alone (left), 0.1%
RA (center), or 0.3% MDI 301 (right). (B) Epidermal thickening.
Values are means and standard deviations based on measure-
ments at four sites in histological sections of three mice per
treatment group. (Inset) Histological appearance of mouse skin
after treatment for 14 days with vehicle alone (left), 0.1% RA
(center), or 0.3% MDI 301 (right) and sacrifice on day 15. Irrita-
tion scores and epidermal thickness values were evaluated by
ANOVA followed by paired group comparisons. n Statistically
significant difference from the control group at p < 0.05.
Figure 2. Epidermal thickness and soluble collagen elaboration
in skin of control mice and mice treated with a combination of
Temovate and MDI 301. (A) Epidermal thickness. Values are
means and standard deviations based on measurements at
four sites in histological sections of three mice per treatment
group. (B) Soluble type I collagen. Values are means and stan-
dard deviations based on organ culture fluids from four animals
per group. (Inset) Western blot examples of soluble collagen
elaborated by organ-cultured skin from control mice (lane 1),
mice treated with Temovate alone (lane 2), Temovate plus
0.3% MDI 301 (lane 3) or Temovate plus 1.0% MDI 301 (lane
4). Epidermal thickness values and soluble collagen values
were evaluated by ANOVA followed by paired group compari-
sons. n Statistically significant difference from the control group
at p < 0.05; nn Statistically significant difference from the Tem-
ovate alone group at p < 0.05.
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wounding was done at the end of the retinoid-treatment
phase. Consistent with past results,17 wound closure was
slower in the diabetic rats than in controls. It can be seen
from Figure 3B that in diabetic rats pretreated for 14 days
with 0.3% MDI 301, the average time to wound-closure
time was reduced as compared with that seen in diabetic
rats treated with vehicle alone. Differences between ret-
inoid-treated and vehicle-treated rats were evident by day
3 and statistically significant by day 5.
Figure 3C compares healing of superficial skin wounds
In young rats and aged rats treated for 14 days with 0.3%
MDI 301 or with vehicle alone. The findings from this
study are similar to findings from the other two models.
Abrasion wound healing was significantly slower in skin of
aged rats than in the skin of young controls. As in the oth-
er two models, topical pretreatment of the aged rats with
MDI 301 substantially improved healing rates.
Type I collagen and MMP-2/MMP-9 were assessed in
skin biopsies taken at the time of wound closure in all three
models. With corticosteroid treated rats, skin biopsies
were taken from four sites. Biopsy site one was from the
area just beyond the initial wound margin; sites two and
three were within the initial area encompassed by the abra-
sion wound and site four was from an area not exposed to
Temovate or MDI 301 (and not abraded). Figure 4 com-
pares levels of soluble type I collagen in organ culture flu-
ids (corticosteroid-treated animals) and levels of the two
MMPs are shown in Figure 5. Collagen levels were higher
and MMP levels were lower in the culture fluids from bi-
opsies of the retinoid-treated skin than in culture fluids
from vehicle-treated animals. Table 1 summarizes the
effects of MDI 301 on type I collagen and MMP levels in
skin taken from control and treated diabetic rats and from
control and treated aged rats. Consistent with what was
seen in the corticosteroid model (Figures 4 and 5), organ
culture fluids from MDI 301-treated skin had higher col-
lagen levels and lower MMP levels than did culture fluid
from vehicle-treated control skin.
DISCUSSION
In the present study, MDI 301, an experimental retinoid,
was applied daily to the skin of rats treated with the potent
corticosteroid, Temovate (clobetasol propionate), to the
skin of diabetic rats (8 weeks posttreatment with STZ) and
to the skin of aged rats (14–16 months old). In all three
models, subsequently induced abrasion wounds healed
more rapidly in the retinoid-treated animals than in vehi-
cle-treated controls. In all three models, type I collagen
levels increased and MMP levels decreased in response to
Figure 3. (A) Abrasion wound healing in control hairless rats
and hairless rats treated with Temovate plus vehicle or Tem-
ovate plus 0.3% MDI 301. Values represent the percentage of
the wound that is closed and scab-free at each time point. Val-
ues are based on nine animals per group. Values from the three
groups were evaluated statistically (ANOVA followed by paired
group comparisons). n Statistically significant difference from
the Temovate alone group at p < 0.05. (B) Abrasion wound
healing in hairless rats in the STZ model of diabetes. Treatment
groups include nondiabetic rats as well as diabetic rats treated
with vehicle or with 0.3% MDI 301. Values represent the per-
centage of the wound that is closed and scab-free at each time
point. Values are based on 9–11 animals per group. Values from
the three groups were evaluated statistically (ANOVA followed
by paired group comparisons). n Statistically significant differ-
ence from the diabetic alone group at p < 0.05. (C) Abrasion
wound healing in hairless aged rats. Treatment groups include
young rats as well as aged rats treated with vehicle or with
0.3% MDI 301. Values represent the percentage of the wound
that is closed and scab-free at each time point. Values are
based on three to five animals per group. Values from the three
groups were evaluated statistically (ANOVA followed by paired
group comparisons). n Statistically significant difference from
the aged animal group at p < 0.05.
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MDI 301. Skin irritation during the retinoid-treatment
phase was virtually nonexistent.
The biologically active retinoids have effects on the der-
mis that delay or prevent atrophy. Topical retinoid use in-
duces the synthesis of types I and III procollagen31–33 and
suppresses the major collagen-degrading enzymes in the
skin.34,35 These retinoid effects in the skin reflect multiple
mechanisms. Retinoids directly influence gene transcrip-
tion and alter signaling cascades that regulate gene tran-
scription.36 In the case of MMP reduction, RA not only
down-regulates enzyme production at the molecular lev-
el34,35 but also up-regulates tissue inhibitor of metal-
loproteinases-1 (TIMP-1),37 the major MMP inhibitor in
the skin.38 Along with these specific effects on collagen
metabolism, retinoid treatment also stimulates prolifera-
tion of dermal fibroblasts, thus fostering additional colla-
gen production. Although it is generally believed that
improved wound healing in retinoid-treated skin reflects
these dermal activities, it is important to keep in mind that
retinoids are broad-acting molecules that influence the
functioning of other elements in the skin, as well. Retinoid
treatment increases keratinocyte proliferation and motili-
ty,26,27,39 properties essential for rapid wound closure.
Given the regenerative effects of retinoid use on both the
dermal and epidermal component of the skin, it is not sur-
prising that retinoids should be considered for use as
wound-preventative or wound-healing agents. Several past
studies have, in fact, demonstrated beneficial effects of ret-
inoid use in wound healing. Although most of these studies
have focused on wounds in the skin,11–17 retinoid efficacy
has also been demonstrated in healing of wounds in other
tissues—bone, cornea, respiratory tract, upper digestive
system, and gut.18–25 Although retinoids have beneficial
activities, skin irritation is commonly seen following top-
ical application of RA.26–28 If skin irritation is too severe,
retinoid use will simply be discontinued by most users.
Equally important, excessive irritation may negate benefi-
cial effects that would otherwise be seen, or actually in-
crease sensitivity to wound formation.
In past studies, MDI 301 (a synthetic retinoid) has been
demonstrated to increase epidermal thickness, induce col-
lagen production and inhibit the major collagen-degrading
enzymes in organ cultures of human skin.29 In these re-
gards, MDI 301 and RA are similar. With the synthetic
retinoid, however, surrogate markers of inflammation that
Figure 4. Soluble collagen (Western blotting) in organ culture
fluid of skin from rats treated with Temovate plus vehicle or
Temovate plus 0.3% MDI 301. Biopsy site 1 was from the area
just beyond the initial wound margin; sites 2 and 3 were within
the initial area encompassed by the abrasion wound and site 4
was from an area not exposed to Temovate or MDI 301 (and
not abraded). Values are means and standard deviations based
on organ cultures from nine rats per treatment group. Values
were analyzed for statistical significance using the Student t-
test, comparing each site separately. n Statistically significant
difference from the Temovate alone group at p < 0.05.
Figure 5. MMPs-2 and -9 (gelatin zymography) in organ culture
fluid of skin from rats treated with Temovate plus vehicle or
Temovate plus 0.3% MDI 301. Biopsy site 1 was from the area
just beyond the initial wound margin; sites 2 and 3 were within
the initial area encompassed by the abrasion wound and site 4
was from an area not exposed to Temovate or MDI 301 (and
not abraded). Values are means and standard deviations based
on organ cultures from nine rats per treatment group. Values
were analyzed for statistical significance using the Student t-
test, comparing each site separately. n Statistically significant
difference from the Temovate alone group at p < 0.05. (Inset)
Representative gelatin zymograms of organ culture fluid
from rats treated with Temovate plus vehicle or Temovate plus
MDI 301.
Wound Rep Reg (2008) 16 117–124 c 2008 by the Wound Healing Society122
Nonirritating retinoid Warner et al.
are up-regulated by RA in human skin organ culture are
not increased.29 Given this profile of activities, the use of
MDI 301 in topical preparations should, in theory, have
significant advantages over RA and other retinoids that
are currently available as skin-repair agents. In the present
study we demonstrate that MDI 301 does, in fact, have
wound healing potential. Using three different models of
delayed (impaired) skin wound healing in hairless rats,
pretreatment of the rats for 12–14 days with MDI 301 be-
fore wounding was shown to decrease the time to wound
closure as compared with vehicle-treated control animals.
In all three models, biopsies from the wound site in MDI
301-treated animals (taken at the time of wound closure)
produced higher levels of type I collagen and lower
amounts of MMPs than did wound site biopsies from ve-
hicle-treated animals. The ability of topical MDI 301 to
improve healing of superficial wounds is similar to what
we reported earlier with RA (diabetic model only).17 The
ability of the synthetic retinoid to improve superficial
wound healing in at-risk skin but without the irritation as-
sociated with RA and other currently available agents pro-
vides a strong rational for further development of this
agent as a wound preventative.
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